EU MIA Versus National Authorisations: Roles, Differences And Overlap

EU Manufacturing and Importation Authorisation (MIA) Authorisation required for companies manufacturing or importing medicinal products in the EU. Although referred to as the MIA in practice, this authorisation is always issued by a national competent authority under EU law rather than a single EU-wide licence; understanding the split between EU requirements and national implementation is essential for operators and regulators.

At first glance, the MIA appears to be an "EU" instrument because its legal basis is EU pharmaceutical legislation. In reality, the licence is granted, managed and enforced at Member State level. This means legal obligations derive from EU directives and regulations, but day-to-day implementation — applications, fees, inspections and post-authorisation controls — are performed by national authorities.

Legal Basis Versus Issuing Authority

EU law (for example Directive 2001/83/EC) sets the harmonised framework for manufacturing and import authorisations: it defines core requirements (such as the need for GMP, Qualified Persons and written procedures) and requires Member States to ensure compliance. Member States then transpose these obligations into national administrative processes and designate the competent authority that issues the MIA for sites within their territory.

What Is Harmonised Across The EU

• GMP Standards: Good Manufacturing Practice standards are harmonised through EudraLex Volume 4 and international agreements (PIC/S).
• Qualified Person Duties: The responsibilities of the Qualified Person (QP) for batch release and compliance are defined by EU law.
• Inspection Principles: Core inspection requirements and the role of GMP certificates align across Member States.

What Differs Between Member States

Because MIAs are national licences, procedural and practical differences occur. Expect variation in items such as application forms, dossier detail, fee structures, processing times, translation requirements, and whether the authority publishes inspection reports. Some regulators offer streamlined processes for contract manufacturing organisations or centralised guidance for foreign importers; others require additional local documentation.

When You Need Multiple Authorisations

Companies operating in multiple Member States frequently need separate MIAs for each manufacturing or import site. A single site that produces for the entire EU market still requires an MIA from the Member State where the site is located. Additionally, marketing-authorisation holders must ensure their supply chain partners (manufacturers, importers) hold valid MIAs in the relevant jurisdictions or otherwise meet regulatory requirements.

Import Authorisation Specifics

Import authorisations target activities where non-EU manufacturers supply finished medicines or active substances to EU-based importers. National authorities review whether the importer has systems to verify foreign GMP compliance, appropriate quality agreements with suppliers, and adequate storage and distribution processes. Many Member States require importers to hold documentation from the exporting site such as a valid GMP certificate or inspection report issued or recognised by the competent authority.

How Authorities Coordinate

Coordination happens through EU-level networks and databases: GMP inspection outcomes, mutual recognition mechanisms and information-sharing tools help authorities rely on each other’s decisions. For example, a GMP certificate issued after inspection by one competent authority may be accepted by others under established agreements, reducing duplication. Nevertheless, reliance is not automatic and some national regulators request local inspections or supplemental documentation.

Practical Example

A German importer wants to bring finished products from a Korean manufacturer into the EU. The importer must hold an import authorisation from the German competent authority that documents its ability to verify the Korean site's GMP status. The Korean site’s GMP certificate and related inspection report are evaluated; the German authority may accept these documents if they meet the criteria established under EU guidance and bilateral inspection recognition.

Tips For Managing Cross-Border Complexity

• Map Licences To Activities: Maintain a register showing which country issued each MIA and the activities it covers.
• Align Contracts And Quality Agreements: Clarify responsibilities for batch release, complaints, recalls and pharmacovigilance across jurisdictions.
• Use Recognised Inspection Reports: Where possible, obtain GMP certificates and inspection reports that meet EU/national acceptance criteria to streamline import authorisations.

In short, the EU Manufacturing and Importation Authorisation (MIA) is an EU-law–based licence issued by national competent authorities. The harmonised legal framework sets the standards; national bodies issue, inspect and enforce MIAs. Successful cross-border operations require careful coordination between MIAs, GMP evidence and national procedures.